01/04/2020 Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
The Ministry of Health’s Drug Advisory Committee has recommended:
- Alfuzosin 10 mg tablet and dutasteride 0.5 mg capsule for treating benign prostatic hyperplasia
Subsidy status
RAlfuzosin 10 mg tablet and dutasteride 0.5 mg capsule are recommended for inclusion on the MOH Standard Drug List (SDL).
NRSDL subsidy does not apply to tamsulosin 0.4 mg tablet or dutasteride 0.5 mg/tamsulosin 0.4 mg capsule.